◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HJ SCIENCE-B (6132) Financial History

Name: HJ SCIENCE-B (6132) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-08-10

HJ SCIENCE-B (6132) operates in the Biotechnology industry and is headquartered in Chengdu, China. In the fiscal year ended 2025-12-31, 6132 reported HKD 13M in revenue and (HKD 135M) in net income.

HJ Science Co., Ltd. engages in research and development of new small molecule drugs. The company focuses on metabolic diseases, oncology, and autoimmune disorders.

Interactive charts & full statements →

6132 Revenue & Earnings History — Annual Income Statement

Income statement	2025-12-31	2024-12-31
Total Revenue	HKD 13M	HKD 2M
Operating Income (EBIT)	(HKD 125M)	(HKD 85M)
Net Income	(HKD 135M)	(HKD 202M)

HKD; HKDM / HKDB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

6132 Free Cash Flow History

6132 Balance Sheet History

Balance sheet	2025-12-31	2024-12-31
Total Assets	HKD 433M	HKD 430M
Total Liabilities	HKD 96M	HKD 54M

HKD; HKDM / HKDB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 6132 viewer.

Other Companies in Biotechnology

SLXN · Silexion Therapeutics Corp — $1 million
PTP · Pentixapharm Holding AG N — $1 million
VBIO · Valion Bio, Inc. — $1 million
APM · Aptorum Group Ltd — $1 million
ZBIO · Zenas BioPharma, Inc.
ABBV · AbbVie — $441 billion
6160 · BeOne Medicines AG — $309 billion
AMGN · Amgen — $224 billion

← 6128 All “0-9” companies 6133 →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.